Ha Tay Pharmaceutical JSC - Laporan Laba Rugi (TTM)

Ha Tay Pharmaceutical JSC
VN ˙ HNX
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Ha Tay Pharmaceutical JSC menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
09-30
2024
01-01
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 1,936,713 2,006,475 1,867,492 1,929,218 1,781,911 1,609,364 1,637,143 1,582,890 1,749,385 1,837,395 1,928,912 2,059,424 1,999,304 2,001,416 1,952,464 2,019,408 2,086,353 1,561,096 2,157,264
Change (%) 3.60 -6.93 3.31 -7.64 -9.68 1.73 -3.31 10.52 5.03 4.98 6.77 -2.92 0.11 -2.45 3.43 3.32 -25.18 38.19
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 1,691,236 1,767,422 1,664,863 1,735,603 1,605,146 1,455,342 1,484,222 1,434,769 1,576,727 1,650,138 1,727,351 1,845,429 1,795,972 1,799,532 1,756,825 1,811,680 1,866,534 1,394,124 1,931,015
Change (%) 4.50 -5.80 4.25 -7.52 -9.33 1.98 -3.33 9.89 4.66 4.68 6.84 -2.68 0.20 -2.37 3.12 3.03 -25.31 38.51
% of Revenue 87.33 88.09 89.15 89.96 90.08 90.43 90.66 90.64 90.13 89.81 89.55 89.61 89.83 89.91 89.98 89.71 89.46 89.30 89.51
Gross Operating Profit 245,477 239,053 202,629 193,616 176,765 154,022 152,921 148,121 172,659 187,256 201,561 213,995 203,331 201,884 195,639 207,729 219,818 166,972 226,249
Change (%) -2.62 -15.24 -4.45 -8.70 -12.87 -0.72 -3.14 16.57 8.45 7.64 6.17 -4.98 -0.71 -3.09 6.18 5.82 -24.04 35.50
% of Revenue 12.67 11.91 10.85 10.04 9.92 9.57 9.34 9.36 9.87 10.19 10.45 10.39 10.17 10.09 10.02 10.29 10.54 10.70 10.49
SG&A 138,346 129,633 109,674 104,418 102,830 91,953 92,420 88,844 93,034 84,806 88,306 91,405 104,115 114,712 120,547 131,926 143,306 108,413 154,774
Change (%) -6.30 -15.40 -4.79 -1.52 -10.58 0.51 -3.87 4.72 -8.84 4.13 3.51 13.91 10.18 5.09 9.44 8.63 -24.35 42.76
% of Revenue 7.14 6.46 5.87 5.41 5.77 5.71 5.65 5.61 5.32 4.62 4.58 4.44 5.21 5.73 6.17 6.53 6.87 6.94 7.17
R&D
Change (%)
% of Revenue
OpEx 1,829,582 1,897,055 1,774,537 1,840,021 1,707,975 1,547,294 1,576,642 1,523,613 1,669,761 1,734,944 1,815,657 1,936,834 1,900,088 1,914,245 1,877,372 1,943,606 2,009,840 1,502,537 2,085,789
Change (%) 3.69 -6.46 3.69 -7.18 -9.41 1.90 -3.36 9.59 3.90 4.65 6.67 -1.90 0.75 -1.93 3.53 3.41 -25.24 38.82
% of Revenue 94.47 94.55 95.02 95.38 95.85 96.14 96.30 96.26 95.45 94.42 94.13 94.05 95.04 95.64 96.15 96.25 96.33 96.25 96.69
Operating Income 107,131 109,420 92,955 89,198 73,936 62,070 60,501 59,277 79,625 102,450 113,255 122,590 99,216 87,171 75,092 75,802 76,513 58,560 71,475
Change (%) 2.14 -15.05 -4.04 -17.11 -16.05 -2.53 -2.02 34.33 28.67 10.55 8.24 -19.07 -12.14 -13.86 0.95 0.94 -23.46 22.05
% of Revenue 5.53 5.45 4.98 4.62 4.15 3.86 3.70 3.74 4.55 5.58 5.87 5.95 4.96 4.36 3.85 3.75 3.67 3.75 3.31
Interest Expense -13,480 -13,323 -13,500 -13,846 -13,699 -13,993 -14,907 -14,477 -14,314 -14,304 -15,548 -22,156 -20,099 -18,439 -15,239 -14,344 -13,449 -9,465 -14,147
Change (%) -1.16 1.33 2.56 -1.07 2.15 6.53 -2.88 -1.13 -0.07 8.70 42.50 -9.28 -8.26 -17.35 -5.87 -6.24 -29.63 49.47
% of Revenue -0.70 -0.66 -0.72 -0.72 -0.77 -0.87 -0.91 -0.91 -0.82 -0.78 -0.81 -1.08 -1.01 -0.92 -0.78 -0.71 -0.64 -0.61 -0.66
Net Income 89,424 92,048 81,610 82,433 72,148 67,946 65,703 64,971 79,139 95,211 102,908 104,458 85,056 77,026 66,840 69,306 71,772 54,033 72,936
Change (%) 2.93 -11.34 1.01 -12.48 -5.82 -3.30 -1.11 21.81 20.31 8.08 1.51 -18.57 -9.44 -13.22 3.69 3.56 -24.72 34.98
% of Revenue 4.62 4.59 4.37 4.27 4.05 4.22 4.01 4.10 4.52 5.18 5.34 5.07 4.25 3.85 3.42 3.43 3.44 3.46 3.38

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista